Galectin Therapeutics Inc. (NASDAQ: GALT)
$2.53
+0.1500 ( +6.30% ) 116.3K
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Market Data
Open
$2.53
Previous close
$2.38
Volume
116.3K
Market cap
$138.59M
Day range
$2.38 - $2.53
52 week range
$1.35 - $4.27
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 01, 2023 |
5 | Other | 1 | Dec 01, 2023 |
4 | Insider transactions | 1 | Nov 15, 2023 |
10-q | Quarterly Reports | 59 | Nov 13, 2023 |
8-k/a | 8K-related | 14 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 13, 2023 |
4 | Insider transactions | 1 | Oct 31, 2023 |
4 | Insider transactions | 1 | Oct 16, 2023 |
4/a | Other | 1 | Oct 16, 2023 |
def | Proxies and info statements | 8 | Oct 06, 2023 |